menu
    • menu

    Company profile for Almirall

    NEW Drugs in Dev: 26
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Almirall is a pharmaceutical company committed to providing valuable medicines to patients worldwide. We research, develop, manufacture and market proprietary medicines as well as licensed products, in areas with unmet medical needs. Today, our products are available in over 70 countries on five continents, through our 14 affiliates and a strategic partnership network.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlmirallSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Ronda General Mitre, 151 08022 Barcelona
    Telephone
    Telephone
    +34 93 291 30 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.almirall.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/almirall/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Bio-Europe Spring

    Bio-Europe Spring

    Not Confirmed

    envelop Contact Supplier

    Bio-Europe Spring

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lebrikizumab Shows 4-Year Control In Atopic Dermatitis
    Lebrikizumab Shows 4-Year Control In Atopic Dermatitis

    27 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260327314744/en/Lebrikizumab-delivered-long-term-disease-control-for-up-to-four-years-in-patients-with-moderate-to-severe-atopic-dermatitis

    BUSINESSWIRE
    27 Mar 2026
    Share Share
    Almirall 17th Skin Academy Highlights Advances In Skin Diseases
    Almirall 17th Skin Academy Highlights Advances In Skin Diseases

    23 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-23/almiralls-17th-skin-academy-highlights-scientific-advances-in-inflammatory-skin-diseases-and-skin-c

    PHARMIWEB
    23 Mar 2026
    Share Share
    Almirall Inaugurates Offices In China To Advance Innovation
    Almirall Inaugurates Offices In China To Advance Innovation

    12 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260312083794/en/Almirall-Inaugurates-Offices-in-China-to-Advance-Innovation-in-Medical-Dermatology-Through-Partnerships

    BUSSINESSWIRE
    12 Mar 2026
    Share Share
    Almirall Releases 2025 Financial Results
    Almirall Releases 2025 Financial Results

    23 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-23/almirall-s-2025-results

    PHARMIWEB
    23 Feb 2026
    Share Share
    Almirall Approves Seysara In China For Moderate-To-Severe Acne
    Almirall Approves Seysara In China For Moderate-To-Severe Acne

    30 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260128234524/en/Almirall-Announces-the-Approval-of-Seysara-in-China-for-the-Treatment-of-Moderate-to-Severe-Acne

    BUSINESSWIRE
    30 Jan 2026
    Share Share
    Almirall Starts Lebrikizumab's Phase 3 LumiNE in Nummular Eczema
    Almirall Starts Lebrikizumab's Phase 3 LumiNE in Nummular Eczema

    15 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260114791875/en/Almirall-Announces-LumiNE-a-Phase-III-Clinical-Study-Assessing-the-Efficacy-of-Lebrikizumab-for-the-Treatment-of-Nummular-Eczema

    BUSINESSWIRE
    15 Jan 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Almirall and get a quotation

    Almirall is a supplier offers 8 products (APIs, Excipients or Intermediates).

    Find a price of Aclidinium Bromide bulk with DMF, JDMF offered by Almirall

    Find a price of Ebastine bulk with CEP, JDMF offered by Almirall

    Find a price of Aceclofenac bulk with CEP offered by Almirall

    Find a price of Ebastine bulk with CEP offered by Almirall

    Find a price of Almotriptan Malate bulk offered by Almirall

    Find a price of LAS 34475 bulk offered by Almirall

    Find a price of Almotriptan bulk offered by Almirall

    Find a price of Ebastine bulk offered by Almirall

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search